Glaucoma Therapeutics Market

Glaucoma Therapeutics Market (Drug Class - Prostaglandins, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, Combination Medications, Cholinergics; End use - Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

  • Rep Id : TMRGL16406
  • Published On : Aug 2018
  • No. of Pages : 185
  • Category : Pharmaceutical

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Glaucoma Therapeutics Market

4. Market Overview
     4.1. Introduction
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Glaucoma Therapeutics Market Analysis and Forecasts, 2016–2026
     4.5. Porter’s Five Force Analysis

5. Market Outlook
     5.1. Value Chain Analysis
     5.2. Disease Prevalence & Incidence Rate, by Region
     5.3. Healthcare Industry Overview
     5.4. Pipeline Analysis

6. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Drug Class
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. Prostaglandins
            6.3.2. Beta Blockers
            6.3.3. Alpha Agonists
            6.3.4. Carbonic Anhydrase Inhibitors
            6.3.5. Combination Medications
            6.3.6. Cholinergics
     6.4. Market Attractiveness, by Drug Class

7. Global Glaucoma Therapeutics Market Analysis and Forecasts, by End-user
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast, by End-user, 2016–2026
            7.3.1. Hospitals
            7.3.2. Ophthalmic Clinics
            7.3.3. Ambulatory Surgical Centers
     7.4. Market Attractiveness, by End-user

8. Global Glaucoma Therapeutics Market Analysis and Forecasts, by Region
     8.1. Key Findings
     8.2. Market Value Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
     8.3. Market Attractiveness, by Country/Region

9. North America Glaucoma Therapeutics Market Analysis and Forecast
     9.1. Introduction
     9.2. Market Value Forecast, by Drug Class, 2016–2026
            9.2.1. Prostaglandins
            9.2.2. Beta Blockers
            9.2.3. Alpha Agonists
            9.2.4. Carbonic Anhydrase Inhibitors
            9.2.5. Combination Medications
            9.2.6. Cholinergics
     9.3. Market Value Forecast, by End-user, 2016–2026
            9.3.1. Hospitals
            9.3.2. Ophthalmic Clinics
            9.3.3. Ambulatory Surgical Centers
     9.4. Market Value Forecast, by Country, 2016–2026
            9.4.1. U.S.
            9.4.2. Canada
     9.5. Market Attractiveness Analysis
            9.5.1. By Drug Class
            9.5.2. By End-user
            9.5.3. By Country

10. Europe Glaucoma Therapeutics Market Analysis and Forecast
     10.1. Introduction
     10.2. Market Value Forecast, by Drug Class, 2016–2026
            10.2.1. Prostaglandins
            10.2.2. Beta Blockers
            10.2.3. Alpha Agonists
            10.2.4. Carbonic Anhydrase Inhibitors
            10.2.5. Combination Medications
            10.2.6. Cholinergics
     10.3. Market Value Forecast, by End-user, 2016–2026
            10.3.1. Hospitals
            10.3.2. Ophthalmic Clinics
            10.3.3. Ambulatory Surgical Centers
     10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Spain
            10.4.5. Italy
            10.4.6. Rest of Europe
     10.5. Market Attractiveness Analysis
            10.5.1. By Drug Class
            10.5.2. By End-user
            10.5.3. By Country/Sub-region

11. Asia Pacific Glaucoma Therapeutics Market Analysis and Forecast
     11.1. Introduction
     11.2. Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. Prostaglandins
            11.2.2. Beta Blockers
            11.2.3. Alpha Agonists
            11.2.4. Carbonic Anhydrase Inhibitors
            11.2.5. Combination Medications
            11.2.6. Cholinergics
     11.3. Market Value Forecast, by End-user, 2016–2026
            11.3.1. Hospitals
            11.3.2. Ophthalmic Clinics
            11.3.3. Ambulatory Surgical Centers
     11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. Japan
            11.4.3. India
            11.4.4. Australia & New Zealand
            11.4.5. Rest of Asia Pacific
     11.5. Market Attractiveness Analysis
            11.5.1. By Drug Class
            11.5.2. By End-user
            11.5.3. By Country/Sub-region

12. Latin America Glaucoma Therapeutics Market Analysis and Forecast
     12.1. Introduction
     12.2. Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. Prostaglandins
            12.2.2. Beta Blockers
            12.2.3. Alpha Agonists
            12.2.4. Carbonic Anhydrase Inhibitors
            12.2.5. Combination Medications
            12.2.6. Cholinergics
     12.3. Market Value Forecast, by End-user, 2016–2026
            12.3.1. Hospitals
            12.3.2. Ophthalmic Clinics
            12.3.3. Ambulatory Surgical Centers
     12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of Latin America
     12.5. Market Attractiveness Analysis
            12.5.1. By Drug Class
            12.5.2. By End-user
            12.5.3. By Country/Sub-region

13. Middle East & Africa Glaucoma Therapeutics Market Analysis and Forecast
     13.1. Introduction
     13.2. Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. Prostaglandins
            13.2.2. Beta Blockers
            13.2.3. Alpha Agonists
            13.2.4. Carbonic Anhydrase Inhibitors
            13.2.5. Combination Medications
            13.2.6. Cholinergics
     13.3. Market Value Forecast, by End-user, 2016–2026
            13.3.1. Hospitals
            13.3.2. Ophthalmic Clinics
            13.3.3. Ambulatory Surgical Centers
     13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of Middle East & Africa
     13.5. Market Attractiveness Analysis
            13.5.1. By Drug Class
            13.5.2. By End-user
            13.5.3. By Country/Sub-region

14. Competition Landscape
     14.1. Market Player - Competition Matrix
     14.2. Market Share Analysis, by Company (2016)
     14.3. Company Profiles
            14.3.1. Allergan plc
                     14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.1.2 Financial Overview
                     14.3.1.3 Product Portfolio
                     14.3.1.4 SWOT Analysis
                     14.3.1.5 Strategic Overview
            14.3.2. Merck & Co., Inc.
                     14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.2.2 Financial Overview
                     14.3.2.3 Product Portfolio
                     14.3.2.4 SWOT Analysis
                     14.3.2.5 Strategic Overview
            14.3.3. Novartis AG
                     14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.3.2 Financial Overview
                     14.3.3.3 Product Portfolio
                     14.3.3.4 SWOT Analysis
                     14.3.3.5 Strategic Overview
            14.3.4. Pfizer Inc.
                     14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.4.2 Financial Overview
                     14.3.4.3 Product Portfolio
                     14.3.4.4 SWOT Analysis
                     14.3.4.5 Strategic Overview
            14.3.5. Santen Pharmaceuticals Co. Ltd.
                     14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.5.2 Financial Overview
                     14.3.5.3 Product Portfolio
                     14.3.5.4 SWOT Analysis
                     14.3.5.5 Strategic Overview
            14.3.6. Valeant Pharmaceuticals International, Inc.
                     14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.6.2 Financial Overview
                     14.3.6.3 Product Portfolio
                     14.3.6.4 SWOT Analysis
                     14.3.6.5 Strategic Overview
            14.3.7. Aerie Pharmaceuticals Inc.
                     14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
                     14.3.7.2 Product Portfolio
                     14.3.7.3 SWOT Analysis
                     14.3.7.4 Strategic Overview

List of Tables

Table 01: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 02: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 03: Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 04: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 05: North America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 06: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 07: U.S. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 08: U.S. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 09: Canada Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 10: Canada Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 11: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 12: Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 13: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: U.K. Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 15: U.K. Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 16: Germany Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 17: Germany Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 18: France Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 19: France Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 20: Spain Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 21: Spain Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 22: Italy Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 23: Italy Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 24: Rest of Europe Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 25: Rest of Europe Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 26: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 27: Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 28: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29: Japan Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 30: Japan Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 31: China Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 32: China Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 33: India Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 34: India Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 35: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 36: Australia & New Zealand Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 37: Rest of APAC Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 38: Rest of APAC Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 39: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 40: Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 41: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 42: Brazil Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 43: Brazil Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 44: Mexico Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 45: Mexico Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 46: Rest of LATAM Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 47: Rest of LATAM Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 48: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
Table 49: Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 50: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 51: GCC Countries Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 52: GCC Countries Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 53: South Africa Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 54: South Africa Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026
Table 55: Rest of MEA Glaucoma Therapeutics Market Forecast, by Drug Class, 2016–2026
Table 56: Rest of MEA Glaucoma Therapeutics Market Forecast, by End-user, 2016–2026

List of Figures

Figure 01: Global Glaucoma Therapeutics Market Snapshot
Figure 02: Global Glaucoma Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
Figure 03: Market Value Share, by Drug Class (2017)
Figure 04: Market Value Share, by End-user (2017)
Figure 05: Market Value Share, by Region (2017)
Figure 06: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 07: Global Prostaglandins Market Revenue (US$ Mn), 2016–2026
Figure 08: Global Beta Blockers Market Revenue (US$ Mn), 2016–2026
Figure 09: Global Alpha Agonist Market, Revenue (US$ Mn), 2016–2026
Figure 10: Global Carbonic Anhydrase Inhibitor (CAI) Market, Revenue (US$ Mn), 2016–2026
Figure 11: Global Combination Medications Market, Revenue (US$ Mn), 2016–2026
Figure 12: Global Cholinergic Market, Revenue (US$ Mn), 2016–2026
Figure 13: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 14: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 15: Global Hospitals Market Revenue (US$ Mn), 2016–2026
Figure 16: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2016–2026
Figure 17: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2016–2026
Figure 18: Global Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 19: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2017 and 2026
Figure 20: Global Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 21: North America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 22: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country
Figure 23: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 24: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 25: North America Glaucoma Therapeutics Market, by Country, 2017 and 2026
Figure 26: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 27: North America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 28: Europe Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 29: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 30: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 31: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 32: Europe Glaucoma Therapeutics Market, by Country/Sub-region
Figure 33: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 34: Europe Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 36: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-Region
Figure 37: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 38: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 39: Asia Pacific Glaucoma Therapeutics Market, by Country/Sub-region
Figure 40: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 41: Asia Pacific Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 42: Latin America Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 43: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 44: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 45: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 46: North America Glaucoma Therapeutics Market, by Country/Sub-region
Figure 47: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 48: Latin America Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 50: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region
Figure 51: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
Figure 52: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2017 and 2026
Figure 53: Middle East & Africa Glaucoma Therapeutics Market, by Country/Sub-region
Figure 54: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 55: Middle East & Africa Glaucoma Therapeutics Glaucoma Therapeutics Market Attractiveness Analysis, by End-user
Figure 56: Global Glaucoma Therapeutics Market Share Analysis, by Company (2017)

.